← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	961	+43	+5%	$45.6B
2	2 Danaher DHR $158B	939	+50	+6%	$47.1B
3	3 Novartis NVS $279B	919	+44	+5%	$22B
4	4 Agilent Technologies A $49.1B	565	-14	-2%	$11.6B
5	5 Illumina ILMN $41B	532	+52	+11%	$25B
6	6 Regeneron Pharmaceuticals REGN $80.1B	512	+38	+8%	$29.6B
7	7 Revvity RVTY $17B	331	+7	+2%	$4.59B
8	8 Ionis Pharmaceuticals IONS $7.1B	285	+45	+19%	$6.41B
9	9 Myriad Genetics MYGN $397M	273	-3	-1%	$3.25B
10	10 Charles River Laboratories CRL $14.4B	252	-3	-1%	$2.95B
11	11 Alnylam Pharmaceuticals ALNY $30B	216	+30	+16%	$5.63B
12	12 Bruker BRKR $8.47B	171	-32	-16%	$2.29B
13	13 DELISTED bluebird bio BLUE	169	+46	+37%	$2.74B
14	14 DELISTED SANGAMO THERAPEUTICS INC SGMO	158	+1	+0.6%	$747M
15	15 Azenta AZTA $1.63B	149	+6	+4%	$804M
16	16 PTC Therapeutics PTCT $4.98B	132	+33	+33%	$1.47B
17	17 Sarepta Therapeutics SRPT $1.78B	120	-3	-2%	$359M
18	ISEE 18 DELISTED IVERIC bio, Inc. Common Stock ISEE	116	+24	+26%	$1.36B
19	19 Precigen PGEN $2.63B	108	+6	+6%	$2.49B
20	20 Pacific Biosciences PACB $619M	101	+13	+15%	$342M
21	21 Arrowhead Research ARWR $8.25B	100	-10	-9%	$260M
22	22 Standard BioTools LAB $248M	100	+1	+1%	$1.02B
23	23 Ultragenyx Pharmaceutical RARE $1.47B	100	0	0%	$1.23B
24	24 DELISTED CATALENT, INC. CTLT	94	+14	+18%	$3.27B
25	25 DELISTED Adverum Biotechnologies ADVM	84	+26	+45%	$727M